Anti-PD-1/PD-L1 therapy, one of the most clinically advanced ICIs, has shown limited response rates in TNBC due to primary resistance, insufficient T-cell infiltration, and the immunosuppressive “cold tumor” microenvironment. This evidence concerns the gene PDCD1 and neoplasm.